588 related articles for article (PubMed ID: 32997098)
1. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
Kaplovitch E; Eikelboom JW; Dyal L; Aboyans V; Abola MT; Verhamme P; Avezum A; Fox KAA; Berkowitz SD; Bangdiwala SI; Yusuf S; Anand SS
JAMA Cardiol; 2021 Jan; 6(1):21-29. PubMed ID: 32997098
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Anand SS; Bosch J; Eikelboom JW; Connolly SJ; Diaz R; Widimsky P; Aboyans V; Alings M; Kakkar AK; Keltai K; Maggioni AP; Lewis BS; Störk S; Zhu J; Lopez-Jaramillo P; O'Donnell M; Commerford PJ; Vinereanu D; Pogosova N; Ryden L; Fox KAA; Bhatt DL; Misselwitz F; Varigos JD; Vanassche T; Avezum AA; Chen E; Branch K; Leong DP; Bangdiwala SI; Hart RG; Yusuf S;
Lancet; 2018 Jan; 391(10117):219-229. PubMed ID: 29132880
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban in Peripheral Artery Disease after Revascularization.
Bonaca MP; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Patel MR; Fanelli F; Capell WH; Diao L; Jaeger N; Hess CN; Pap AF; Kittelson JM; Gudz I; Mátyás L; Krievins DK; Diaz R; Brodmann M; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR
N Engl J Med; 2020 May; 382(21):1994-2004. PubMed ID: 32222135
[TBL] [Abstract][Full Text] [Related]
4. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.
Anand SS; Caron F; Eikelboom JW; Bosch J; Dyal L; Aboyans V; Abola MT; Branch KRH; Keltai K; Bhatt DL; Verhamme P; Fox KAA; Cook-Bruns N; Lanius V; Connolly SJ; Yusuf S
J Am Coll Cardiol; 2018 May; 71(20):2306-2315. PubMed ID: 29540326
[TBL] [Abstract][Full Text] [Related]
5. Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry.
Lapébie FX; Aboyans V; Lacroix P; Constans J; Boulon C; Messas E; Ferrières J; Bongard V; Bura-Rivière A
Eur J Vasc Endovasc Surg; 2021 Sep; 62(3):439-449. PubMed ID: 34330647
[TBL] [Abstract][Full Text] [Related]
6. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
Anand SS; Hiatt W; Dyal L; Bauersachs R; Berkowitz SD; Branch KRH; Debus S; Fox KAA; Liang Y; Muehlhofer E; Nehler M; Haskell LP; Patel M; Szarek M; Yusuf S; Eikelboom J; Bonaca MP
Eur J Prev Cardiol; 2022 May; 29(5):e181-e189. PubMed ID: 34463737
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S;
Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD.
Rymer J; Anand SS; Sebastian Debus E; Haskell LP; Hess CN; Jones WS; Muehlhofer E; Berkowitz SD; Bauersachs RM; Bonaca MP; Patel MR
Circulation; 2023 Dec; 148(24):1919-1928. PubMed ID: 37850397
[TBL] [Abstract][Full Text] [Related]
9. Comparison of rivaroxaban-based dual antithrombotic and antiplatelet therapies for symptomatic patients with lower-extremity peripheral artery disease post-revascularization: a retrospective cohort study.
Ji Y; Wang B; Wu G; Zhang Y; Wang Q; Zhou M
Ther Adv Chronic Dis; 2023; 14():20406223231213262. PubMed ID: 38085917
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety.
Hiatt WR; Bonaca MP; Patel MR; Nehler MR; Debus ES; Anand SS; Capell WH; Brackin T; Jaeger N; Hess CN; Pap AF; Berkowitz SD; Muehlhofer E; Haskell L; Brasil D; Madaric J; Sillesen H; Szalay D; Bauersachs R
Circulation; 2020 Dec; 142(23):2219-2230. PubMed ID: 33138628
[TBL] [Abstract][Full Text] [Related]
11. Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial.
Debus ES; Nehler MR; Govsyeyev N; Bauersachs RM; Anand SS; Patel MR; Fanelli F; Capell WH; Brackin T; Hinterreiter F; Krievins D; Nault P; Piffaretti G; Svetlikov A; Jaeger N; Hess CN; Sillesen HH; Conte M; Mills J; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR; Bonaca MP
Circulation; 2021 Oct; 144(14):1104-1116. PubMed ID: 34380322
[TBL] [Abstract][Full Text] [Related]
12. Assessment of clinical and economic impact of rivaroxaban plus aspirin vs. aspirin alone as a secondary prophylaxis in patients with chronic and symptomatic peripheral arterial disease in the United States.
Shah A; Dabbous F; Shah S; Ashton V; Kharat A
J Med Econ; 2024; 27(1):10-15. PubMed ID: 38044632
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
Branch KR; Probstfield JL; Eikelboom JW; Bosch J; Maggioni AP; Cheng RK; Bhatt DL; Avezum A; Fox KAA; Connolly SJ; Shestakovska O; Yusuf S
Circulation; 2019 Aug; 140(7):529-537. PubMed ID: 31163978
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD).
Capell WH; Bonaca MP; Nehler MR; Chen E; Kittelson JM; Anand SS; Berkowitz SD; Debus ES; Fanelli F; Haskell L; Patel MR; Bauersachs R; Hiatt WR
Am Heart J; 2018 May; 199():83-91. PubMed ID: 29754671
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Govsyeyev N; Nehler M; Conte MS; Debus S; Chung J; Dorigo W; Gudz I; Krievins D; Mills J; Moll F; Norgren L; Piffaretti G; Powell R; Szalay D; Sillesen H; Wohlauer M; Szarek M; Bauersachs RM; Anand SS; Patel MR; Capell WH; Jaeger N; Hess CN; Muehlhofer E; Haskell LP; Berkowitz SD; Bonaca MP
J Vasc Surg; 2023 Apr; 77(4):1107-1118.e2. PubMed ID: 36470531
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
Liang Y; Zhu J; Liu L; Anand SS; Connolly SJ; Bosch J; Guzik TJ; O'Donnell M; Dagenais GR; Fox KA; Shestakovska O; Berkowitz SD; Muehlhofer E; Keller L; Yusuf S; Eikelboom JW;
Cardiovasc Res; 2021 Feb; 117(3):942-949. PubMed ID: 32289159
[TBL] [Abstract][Full Text] [Related]
17. Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS.
Bhagirath VC; Eikelboom JW; Anand SS
Future Cardiol; 2018 Nov; 14(6):443-453. PubMed ID: 30417662
[TBL] [Abstract][Full Text] [Related]
18. How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?
Kruger PC; Guzik TJ; Eikelboom JW
Kardiol Pol; 2019 Aug; 77(7-8):661-669. PubMed ID: 31144674
[TBL] [Abstract][Full Text] [Related]
19. Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Greenberg B; Neaton JD; Anker SD; Byra WM; Cleland JGF; Deng H; Fu M; La Police DA; Lam CSP; Mehra MR; Nessel CC; Spiro TE; van Veldhuisen DJ; Vanden Boom CM; Zannad F
JAMA Cardiol; 2019 Jun; 4(6):515-523. PubMed ID: 31017637
[TBL] [Abstract][Full Text] [Related]
20. Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease.
Coleman CI; Kharat AA; Bookhart B; Baker WL
Curr Med Res Opin; 2022 Jan; 38(1):27-34. PubMed ID: 34641745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]